… Even though KRAS mutations were identified in NSCLC tumors more than 20 years ago, we
… KRAS tumor status. Recent studies indicate that patients with mutant KRAS tumors fail to …

… By contrast, even though KRAS mutations were identified in NSCLC tumors more than 20 …
in controlling tumors with KRAS mutations. In 2005, we examined the tumor KRAS status in …

… be a potential therapeutic option in some KRAS mutant tumors. In this review, we highlight
… for treating KRAS mutant mCRC tumors and stratification of KRAS mutations in response to …

… of KRAS mutations, the predictive value of KRAS mutations for therapies, and the integration
of KRAS … than patients with tumors with other KRAS mutations. Although the data related to …

… In this study, we evaluated whether KRAS mutation status … were unable to confirm that
KRAS-driven tumor lines require … in several tumor lines with oncogenic mutations in KRAS but did …

… activate this pathway in KRAS mutant cells due to their ability … -tumor effects in preclinical
models of KRAS mutant cancer, … activity in patients with KRAS mutant tumors, including in …

… KRAS mutation pattern is also tumor type specific. We have compared the top six KRAS
mutant cancer types for exon2 mutation … by G12V mutations are the most frequent across tumor …

… KRAS mutations co-occur commonly with mutations in tumor … co-occurring mutations are
associated with unique tumor … in oncogenic KRAS and the presence of coexisting mutations …

… lines carrying corresponding KRAS mutations. To assess KRAS mutation status in pancreatic
tumor lines, we first confirmed KRAS mutations by direct sequencing of genomic DNA (…

… types of KRAS mutations did not differ between primary tumors and … of the KRAS mutation
status during tumor dissemination. Moreover, a selection of certain types of KRAS mutations …